Streetbeat News

SKYE

Skye Bioscience Inc

https://www.emeraldbio.life/

CEO

Brian Murphy

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.

Open

2.49

Mkt cap

75M

Volume

3.9K

High

2.52

P/E Ratio

4.64

52-wk high

17.65

Low

2.44

Div yield

N/A

52-wk low

2.31

Skye Bioscience, a clinical-stage biotechnology company, will announce its 2024 financial results on March 20, 2025. The company will host a conference call to discuss the results after releasing an earnings press release post-market close.

Portfolio Pulse from

March 14, 2025 | 11:15 am

Skye Bioscience's Nimacimab shows promising Phase 1 safety data and is in Phase 2 trials, potentially revolutionizing obesity treatment with minimal neuropsychiatric side effects. The drug's design avoids issues seen in earlier CB1 inhibitors and suggests fat-specific weight loss, lean muscle preservation, and appetite regulation.

Portfolio Pulse from

December 10, 2024 | 1:45 pm

Skye Bioscience, Inc. (NASDAQ:SKYE) held its Q3 2024 earnings conference call on November 7, 2024. Key company participants included Bernie Hertel, Punit Dhillon, Kaitlyn Arsenault, Chris Twitty, and Dr. Puneet Arora. Analysts from Piper Sandler, Oppenheimer, ScotiaBank, Craig-Hallum, and Cantor Fitzgerald participated in the call.

Portfolio Pulse from

November 08, 2024 | 4:00 am

Skye Bioscience, a clinical-stage biopharmaceutical company, reported its financial results for Q3 2024 and highlighted recent corporate achievements.

Portfolio Pulse from

November 07, 2024 | 9:15 pm

Scotiabank has initiated coverage on Skye Bioscience with a Sector Outperform rating and set a price target of $20.